Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status.
about
Molecular pathological epidemiology in diabetes mellitus and risk of hepatocellular carcinomaA Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.PARP inhibitors as antitumor agents: a patent update (2013-2015).PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy.
P2860
Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Treatment with the PARP inhibi ...... regardless of MSI/MSS status.
@en
type
label
Treatment with the PARP inhibi ...... regardless of MSI/MSS status.
@en
prefLabel
Treatment with the PARP inhibi ...... regardless of MSI/MSS status.
@en
P2093
P2860
P1476
Treatment with the PARP inhibi ...... regardless of MSI/MSS status.
@en
P2093
Apryle M Kuznicki
Brian M Dolinski
Paula Andrade
Ronan C O'Hagan
Sybil M Genther Williams
P2860
P2888
P356
10.1186/S12935-015-0162-8
P577
2015-02-04T00:00:00Z
P5875
P6179
1036996806